Assessing medication use patterns in patients hospitalised with COVID-19: a retrospective study
Objective To describe patterns of medication use—that is, dexamethasone; remdesivir; and tocilizumab—in the management of patients hospitalised with COVID-19.Design and setting Retrospective observational study, using routinely collected, linked electronic data from clinical practice in Scotland. Da...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-12-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/12/12/e064320.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850192271595536384 |
|---|---|
| author | Aziz Sheikh Chris Robertson Holly Tibble Colin R Simpson Marion Bennie Amanj Kurdi Stuart McTaggart Tanja Mueller Elliott Hall Ian Bullard Jo Wapshott Anna Goodfellow Niketa Platt Euan Proud |
| author_facet | Aziz Sheikh Chris Robertson Holly Tibble Colin R Simpson Marion Bennie Amanj Kurdi Stuart McTaggart Tanja Mueller Elliott Hall Ian Bullard Jo Wapshott Anna Goodfellow Niketa Platt Euan Proud |
| collection | DOAJ |
| description | Objective To describe patterns of medication use—that is, dexamethasone; remdesivir; and tocilizumab—in the management of patients hospitalised with COVID-19.Design and setting Retrospective observational study, using routinely collected, linked electronic data from clinical practice in Scotland. Data on drug exposure in secondary care has been obtained from the Hospital Electronic Prescribing and Medicines Administration System.Participants Patients being treated with the drugs of interest and hospitalised for COVID-19 between 1 March 2020 and 10 November 2021.Outcomes Identification of patients subject to the treatments of interest; summary of patients’ baseline characteristics; description of medication use patterns and treatment episodes. Analyses were descriptive in nature.Results Overall, 4063 patients matching the inclusion criteria were identified in Scotland, with a median (IQR) age of 64 years (52–76). Among all patients, 81.4% (n=3307) and 17.8% (n=725) were treated with one or two medicines, respectively; dexamethasone monotherapy accounted for the majority (n=3094, 76.2%) followed by dexamethasone in combination with tocilizumab (n=530, 13.0%). Treatment patterns were variable over time but roughly followed the waves of COVID-19 infections; however, the different drugs were used to varying degrees during the study period.The median (IQR) treatment duration differed by medicine: dexamethasone 5 days (2–9); remdesivir 5 days (2–5); and tocilizumab 1 day (1–1). The overall median (IQR) length of hospital stay among all patients included in the study cohort was 9 days (5–17); 24.7% of patients died in hospital.Conclusion The use of adjuvant medicines in patients hospitalised with COVID-19 appears in line with evolving evidence and changing treatment guidelines. In-hospital electronic prescribing systems are a valuable source of information, providing detailed patient-level data on in-hospital drug use. |
| format | Article |
| id | doaj-art-359c0b7baef34439bb734cdbc97f327c |
| institution | OA Journals |
| issn | 2044-6055 |
| language | English |
| publishDate | 2022-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-359c0b7baef34439bb734cdbc97f327c2025-08-20T02:14:38ZengBMJ Publishing GroupBMJ Open2044-60552022-12-01121210.1136/bmjopen-2022-064320Assessing medication use patterns in patients hospitalised with COVID-19: a retrospective study 0Aziz Sheikh1Chris Robertson2Holly Tibble3Colin R Simpson4Marion Bennie5Amanj Kurdi6Stuart McTaggart7Tanja Mueller8Elliott Hall9Ian Bullard10Jo Wapshott11Anna Goodfellow12Niketa Platt13Euan Proud14SPRinG Network, Severn and Peninsula Deaneries, UKBREATHE Hub, HDR UK, Edinburgh, UKUniversity of Strathclyde, Glasgow, UK1 The University of Edinburgh Usher Institute of Population Health Sciences and Informatics, Edinburgh, UKVictoria University of Wellington, Wellington, Wellington, New ZealandClinical and Protecting Health Directorate, Public Health Scotland, Edinburgh, UKPublic Health Scotland Glasgow Office, Glasgow, UKPublic Health Scotland, Edinburgh, UKStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UKClinical and Protecting Health Directorate, Public Health Scotland Glasgow Office, Glasgow, UKNHS Digital, Leeds, UKNHS Digital, Leeds, UKNHS Digital, Leeds, UKPublic Health Scotland Glasgow Office, Glasgow, UKPublic Health Scotland Glasgow Office, Glasgow, UKObjective To describe patterns of medication use—that is, dexamethasone; remdesivir; and tocilizumab—in the management of patients hospitalised with COVID-19.Design and setting Retrospective observational study, using routinely collected, linked electronic data from clinical practice in Scotland. Data on drug exposure in secondary care has been obtained from the Hospital Electronic Prescribing and Medicines Administration System.Participants Patients being treated with the drugs of interest and hospitalised for COVID-19 between 1 March 2020 and 10 November 2021.Outcomes Identification of patients subject to the treatments of interest; summary of patients’ baseline characteristics; description of medication use patterns and treatment episodes. Analyses were descriptive in nature.Results Overall, 4063 patients matching the inclusion criteria were identified in Scotland, with a median (IQR) age of 64 years (52–76). Among all patients, 81.4% (n=3307) and 17.8% (n=725) were treated with one or two medicines, respectively; dexamethasone monotherapy accounted for the majority (n=3094, 76.2%) followed by dexamethasone in combination with tocilizumab (n=530, 13.0%). Treatment patterns were variable over time but roughly followed the waves of COVID-19 infections; however, the different drugs were used to varying degrees during the study period.The median (IQR) treatment duration differed by medicine: dexamethasone 5 days (2–9); remdesivir 5 days (2–5); and tocilizumab 1 day (1–1). The overall median (IQR) length of hospital stay among all patients included in the study cohort was 9 days (5–17); 24.7% of patients died in hospital.Conclusion The use of adjuvant medicines in patients hospitalised with COVID-19 appears in line with evolving evidence and changing treatment guidelines. In-hospital electronic prescribing systems are a valuable source of information, providing detailed patient-level data on in-hospital drug use.https://bmjopen.bmj.com/content/12/12/e064320.full |
| spellingShingle | Aziz Sheikh Chris Robertson Holly Tibble Colin R Simpson Marion Bennie Amanj Kurdi Stuart McTaggart Tanja Mueller Elliott Hall Ian Bullard Jo Wapshott Anna Goodfellow Niketa Platt Euan Proud Assessing medication use patterns in patients hospitalised with COVID-19: a retrospective study BMJ Open |
| title | Assessing medication use patterns in patients hospitalised with COVID-19: a retrospective study |
| title_full | Assessing medication use patterns in patients hospitalised with COVID-19: a retrospective study |
| title_fullStr | Assessing medication use patterns in patients hospitalised with COVID-19: a retrospective study |
| title_full_unstemmed | Assessing medication use patterns in patients hospitalised with COVID-19: a retrospective study |
| title_short | Assessing medication use patterns in patients hospitalised with COVID-19: a retrospective study |
| title_sort | assessing medication use patterns in patients hospitalised with covid 19 a retrospective study |
| url | https://bmjopen.bmj.com/content/12/12/e064320.full |
| work_keys_str_mv | AT assessingmedicationusepatternsinpatientshospitalisedwithcovid19aretrospectivestudy AT azizsheikh assessingmedicationusepatternsinpatientshospitalisedwithcovid19aretrospectivestudy AT chrisrobertson assessingmedicationusepatternsinpatientshospitalisedwithcovid19aretrospectivestudy AT hollytibble assessingmedicationusepatternsinpatientshospitalisedwithcovid19aretrospectivestudy AT colinrsimpson assessingmedicationusepatternsinpatientshospitalisedwithcovid19aretrospectivestudy AT marionbennie assessingmedicationusepatternsinpatientshospitalisedwithcovid19aretrospectivestudy AT amanjkurdi assessingmedicationusepatternsinpatientshospitalisedwithcovid19aretrospectivestudy AT stuartmctaggart assessingmedicationusepatternsinpatientshospitalisedwithcovid19aretrospectivestudy AT tanjamueller assessingmedicationusepatternsinpatientshospitalisedwithcovid19aretrospectivestudy AT elliotthall assessingmedicationusepatternsinpatientshospitalisedwithcovid19aretrospectivestudy AT ianbullard assessingmedicationusepatternsinpatientshospitalisedwithcovid19aretrospectivestudy AT jowapshott assessingmedicationusepatternsinpatientshospitalisedwithcovid19aretrospectivestudy AT annagoodfellow assessingmedicationusepatternsinpatientshospitalisedwithcovid19aretrospectivestudy AT niketaplatt assessingmedicationusepatternsinpatientshospitalisedwithcovid19aretrospectivestudy AT euanproud assessingmedicationusepatternsinpatientshospitalisedwithcovid19aretrospectivestudy |